What we publish on medicines and when

EMA publishes information on medicines at various stages of their lifecycles, from early development through initial evaluation to post-authorisation changes, safety reviews and withdrawals of authorisation.

Human medicines

Guide to information on human medicines evaluated by EMAGuide to information published on human medicines

EMA's guide describes the different types of information stakeholders can expect on this website about centrally and non-centrally authorised medicines, including the publication times and location:

PDF iconGuide to information on human medicines evaluated by EMA

During the COVID-19 pandemic, EMA is implementing exceptional transparency measures on treatments and vaccines for COVID-19. For more information, see Treatments and vaccines for COVID-19.


Overview of publications and their location

Applications for centralised marketing authorisation


Changes to centralised marketing authorisations


Referrals


Other documents and procedures

Veterinary medicines

Overview of publications and their location

Applications for centralised marketing authorisation


Changes to centralised marketing authorisations


Referrals


Other documents and procedures

Committee agendas and outcomes

How useful was this page?

Add your rating
Average
9 ratings